According to the scientists of the National Research University "BelSU", the obtained results allow us to conclude that the ...

Roche has exercised its option to license a novel capsid from Dyno Therapeutics for use in a gene therapy program for an ...

The capsid license follows an agreement between Dyno and Roche originally announced in May 2020 and marks Dyno’s first adeno-associated virus (AAV) capsid licensing and partnership completion.

Currently, the DMD treatment landscape includes Sarepta’s Elevidys (delandistrogene moxeparvovec), the first FDA-approved ...

Luxturna and other Spark pipeline candidates use an adeno-associated virus vector (AVV) platform to deliver its gene therapy, a distinct technology which Novartis hasn’t built up expertise in.

Explore our new AAV Titer ELISA and AAV Antibody Assay Kits, designed for exceptional specificity, sensitivity, and accuracy ...

Benitec has a market cap of $250mn, $67.8mn in cash, and a cash runway of over 10 quarters, but faces risks due to its small ...

Explore the role of preclinical MRI in studying neurological diseases, with a focus on advanced cellular and molecular ...

The partnership between REGENXBIO and Nippon Shinyaku is more than just a standard collaboration—it’s a bold, forward-looking venture aimed at bringing revolutionary gene therapies to market for rare, ...

Berlin, Germany, and Research Triangle Park, N.C., USA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Not intended for UK <a target=_blank href=https ...